SEC ownership of Eton Pharmaceuticals, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001710340.

Comparable stake leader

EcoR1 Capital, LLC

Disclosed value leader

Opaleye Management Inc.

Comparable rows

50/50

Latest evidence

31 Jul 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
EcoR1 Capital, LLC
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
31 Jul 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001710340
Issuer location
Deer Park, IL

Ownership snapshot

Top shareholders of Eton Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
EcoR1 Capital, LLC
Disclosed value leader
Opaleye Management Inc.
Comparable rows
50/50
Latest evidence
31 Jul 2026
13D/G 13F 3/4/5 Lead comparable stake: 7.7% 13D/G row: EcoR1 Capital, LLC Showing 1-8 of 50 holder rows.

Quick read

EcoR1 Capital, LLC leads the comparable SEC ownership view at 7.7%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens EcoR1 Capital, LLC's linked filing trail.
Comparable ownership Top 5
EcoR1 Capital, LLC 7.7%
BlackRock, Inc. 6.9%
Opaleye Management Inc. 10%
Judith M. Matthews 0.12%
STATE STREET CORP 2.6%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
EcoR1 Capital, LLC
13D/G
7.7%
$28,407,583
1,981,003 shares
$0 31 Dec 2024
BlackRock, Inc.
13F 13D/G
Company
6.9%
from 13D/G
$68,629,156
1,895,833 shares
30 Jun 2026
Opaleye Management Inc.
3/4/5
10%+ Owner
10%
$102,899,116
2,790,000 shares
-$5,831,670 14 Jul 2026
Judith M. Matthews
3/4/5
Chief Financial Officer
0.12%
$142,527
32,246 shares
31 Jul 2026
STATE STREET CORP
13F
Company
13F
2.6%
$25,404,653
701,786 shares
30 Jun 2026
Westside Investment Management, Inc.
13F
Company
13F
1.6%
$15,608,010
431,160 shares
30 Jun 2026
Nuveen, LLC
13F
Company
13F
1.4%
$13,600,593
375,707 shares
30 Jun 2026
THOMPSON SIEGEL & WALMSLEY LLC
13F
Company
13F
1.1%
$10,760,000
297,232 shares
30 Jun 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$15,184,819.

Buys
$0
Insiders: 0
Sells
$15,184,819
Insiders: 5
Net
-$15,184,819
Shares: -466,713
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 466,713
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 425,000 $0 $14,511,105 -$14,511,105
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 41,713 $0 $673,714 -$673,714

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-11 of 11 reporting-owner rows connected to Eton Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
11
Largest Forms 3/4/5 holder
Opaleye Management Inc.
Net 12M change
-$15,184,819
Latest report
31 Jul 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Opaleye Management Inc. 10%+ Owner $102,899,116 -$5,831,670 -5.4% Filing P/S 14 Jul 2026
Sean Brynjelsen President & CEO, Director $38,988,217 -$3,825,717 -8.9% Mixed 31 Jul 2026
Norbert G. Riedel Director $5,535,723 Mixed 31 Jul 2026
James R. Gruber Chief Financial Officer $3,508,134 -$673,714 -16% Mixed 12 Jan 2026
David Krempa Chief Business Officer $1,546,709 -$3,229,923 -68% Mixed 31 Jul 2026
Judith M. Matthews Chief Financial Officer $142,527 Mixed 31 Jul 2026
Paul Maier V Director $44,200 Mixed 31 Jul 2026
Charles J. Casamento Director $44,200 Mixed 31 Jul 2026
Ipek Erdogan-Trinkaus Chief Commercial Officer $40,610 Mixed 31 Jul 2026
Jennifer McKie Adams Director $0 -$1,623,795 -100% Mixed 31 Jul 2026
William Wilson Troutman CFO and Secretary Mixed 07 Feb 2022

Recent insider transactions for Eton Pharmaceuticals, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Charles J. Casamento ETON Common Stock Award 10,000 10,000 31 Jul 2026 Direct
Judith M. Matthews ETON Common Stock Award 32,246 32,246 31 Jul 2026 Direct
Ipek Erdogan-Trinkaus ETON Common Stock Award 80,000 80,000 31 Jul 2026 Direct
Sean Brynjelsen ETON Common Stock Award 128,985 128,985 31 Jul 2026 Direct
David Krempa ETON Common Stock Award 128,985 128,985 31 Jul 2026 Direct
Paul Maier V ETON Common Stock Award 10,000 10,000 31 Jul 2026 Direct
Norbert G. Riedel ETON Common Stock Award 10,000 10,000 31 Jul 2026 Direct
Jennifer McKie Adams ETON Common Stock Award 10,000 10,000 31 Jul 2026 Direct
Opaleye Management Inc. ETON Common Stock, par value $0.001 per share Sale -25% $499,886 $37.54 -13,315 40,000 14 Jul 2026 By Managed Account
Opaleye Management Inc. ETON Common Stock, par value $0.001 per share Sale -0.56% $563,146 $37.54 -15,000 2,665,000 14 Jul 2026 By Opaleye, L.P.
Sean Brynjelsen ETON Common Stock Options Exercise 23.2% 200,000 1,061,194 14 Jul 2026 Direct
Sean Brynjelsen ETON Employee Stock Option Options Exercise 200,000 0 14 Jul 2026 Direct
Sean Brynjelsen ETON Common Stock Options Exercise 3.3% 27,500 861,194 12 Jul 2026 Direct
Sean Brynjelsen ETON Restricted Stock Units Options Exercise -100% -27,500 0 12 Jul 2026 Direct
David Krempa ETON Common Stock Options Exercise 37% 10,000 37,025 12 Jul 2026 Direct
David Krempa ETON Restricted Stock Units Options Exercise -100% -10,000 0 12 Jul 2026 Direct
Opaleye Management Inc. ETON Common Stock, par value $0.001 per share Sale -11.1% $256,522 $38.37 -6,685 53,315 07 Jul 2026 By Managed Account
Opaleye Management Inc. ETON Common Stock, par value $0.001 per share Sale -0.74% $767,456 $38.37 -20,000 2,680,000 07 Jul 2026 By Opaleye, L.P.
Opaleye Management Inc. ETON Common Stock, par value $0.001 per share Sale -0.37% $380,000 $38.00 -10,000 2,700,000 06 Jul 2026 By Opaleye, L.P.
Opaleye Management Inc. ETON Common Stock, par value $0.001 per share Sale -29.4% $934,628 $37.39 -25,000 60,000 02 Jul 2026 By Managed Account
Opaleye Management Inc. ETON Common Stock, par value $0.001 per share Sale -2.34% $2,430,032 $37.39 -65,000 2,710,000 02 Jul 2026 By Opaleye, L.P.
David Krempa ETON Restricted Stock Units Award 11.5% 10,000 96,829 26 Jun 2026 Direct
Jennifer McKie Adams ETON Common Stock Sale -100% $1,623,795 $32.48 -50,000 0 17 Jun 2026 Direct
Jennifer McKie Adams ETON Common Stock Options Exercise 50,000 50,000 17 Jun 2026 Direct
Jennifer McKie Adams ETON Employee Stock Option Options Exercise -100% -50,000 0 17 Jun 2026 Direct
Sean Brynjelsen ETON Common Stock Sale -12.6% $3,825,717 $31.88 -120,000 833,694 28 May 2026 Direct
David Krempa ETON Common Stock Sale -43.8% $619,375 $31.47 -19,679 25,249 27 May 2026 Direct
David Krempa ETON Common Stock Options Exercise 77.9% 19,679 44,928 27 May 2026 Direct
David Krempa ETON Employee Stock Option Options Exercise -100% -19,679 0 27 May 2026 Direct
David Krempa ETON Common Stock Sale -59.8% $1,181,732 $31.49 -37,524 25,249 26 May 2026 Direct
David Krempa ETON Common Stock Options Exercise 148.6% 37,524 62,773 26 May 2026 Direct
David Krempa ETON Employee Stock Option Options Exercise -100% -37,524 0 26 May 2026 Direct
David Krempa ETON Common Stock Sale -62.9% $1,428,816 $33.39 -42,797 25,249 22 May 2026 Direct
David Krempa ETON Common Stock Options Exercise 81.7% 30,591 68,046 22 May 2026 Direct
David Krempa ETON Employee Stock Option Options Exercise -19.6% -30,591 125,609 22 May 2026 Direct
Norbert G. Riedel ETON Common Stock Options Exercise 91.9% 32,155 67,155 21 Apr 2026 Direct
Norbert G. Riedel ETON Employee Stock Option (Right to Buy) Options Exercise -100% -32,155 0 21 Apr 2026 Direct
Norbert G. Riedel ETON Common Stock Exercise of in-the-money or at-the-money derivative security 600% 30,000 35,000 03 Feb 2026 Direct
Norbert G. Riedel ETON Employee Stock Option (Right to Buy) Exercise of in-the-money or at-the-money derivative security -100% -30,000 0 03 Feb 2026 Direct
David Krempa ETON Common Stock Tax liability -0.31% -1,942 630,238 14 Jan 2026 Direct
James R. Gruber ETON Common Stock Tax liability -1.06% -2,293 213,420 14 Jan 2026 Direct
Norbert G. Riedel ETON Restricted Stock Units Award 2.71% 7,757 294,253 12 Jan 2026 Direct
Norbert G. Riedel ETON Employee Stock Option (Right to Buy) Award 4.45% 12,196 286,496 12 Jan 2026 Direct
Jennifer McKie Adams ETON Restricted Stock Units Award 4.55% 7,757 178,086 12 Jan 2026 Direct
Jennifer McKie Adams ETON Employee Stock Option (Right to Buy) Award 7.71% 12,196 170,329 12 Jan 2026 Direct
Charles J. Casamento ETON Restricted Stock Units Award 2.63% 7,757 302,928 12 Jan 2026 Direct
Charles J. Casamento ETON Employee Stock Option (Right to Buy) Award 4.31% 12,196 295,171 12 Jan 2026 Direct
Paul Maier V ETON Restricted Stock Units Award 2.71% 7,757 294,253 12 Jan 2026 Direct
Paul Maier V ETON Employee Stock Option (Right to Buy) Award 4.45% 12,196 286,496 12 Jan 2026 Direct
Ipek Erdogan-Trinkaus ETON Restricted Stock Units Award 20.9% 25,856 149,734 12 Jan 2026 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .